Skip to main content
Log in

Leitsymptom Vertigo

Medikamentöse Therapie bei Schwindel: Was gibt es Neues?

  • Fortbildung
  • Published:
DNP - Der Neurologe & Psychiater Aims and scope

Trotz hoher klinischer Relevanz besteht eine Unter- und Fehlversorgung des Leitsymptoms Schwindel. Häufig werden zu viele, unwirksame und rein symptomatische Medikamente eingesetzt. Es gibt jedoch effektive Therapien gegen peripher- und zentral-vestibuläre Schwindelsyndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Neuhauser HK. Epidemiology of vertigo. Curr Opin Neurol 2007;20:40–6

    Article  Google Scholar 

  2. Brandt T, Dieterich M, Strupp M. Vertigo - Leitsymptom Schwindel, 2. Auflage ed. Heidelberg: Springer Medizin, 2012

    Google Scholar 

  3. Strupp M, Brandt T. Leitsymptom Schwindel: Diagnose und Therapie. Dtsch Ärzteblatt 2008;105:173–80

    Google Scholar 

  4. Rieger A, Mansmann U, Maier W, et al. [Management of patients with the cardinal symptom dizziness or vertigo]. Gesundheitswesen 2014;76:e32–e38

    CAS  PubMed  Google Scholar 

  5. Grill E, Strupp M, Muller M, Jahn K. Health services utilization of patients with vertigo in primary care: a retrospective cohort study. J Neurol 2014;261:1492–98

    Article  Google Scholar 

  6. Strupp M, Dieterich M, Zwergal A, Brandt T. Diagosis and treatment of vestibular disorders. Nervenarzt 2015;86:1277–90

    Article  CAS  Google Scholar 

  7. Bisdorff AR, Staab JP, Newman-Toker DE. Overview of the International Classification of Vestibular Disorders. Neurol Clin 2015;33:541–50

    Article  Google Scholar 

  8. von Brevern M, Bertholon P, Brandt T, Fife T, Imai T, Nuti D, Newman-Toker D. Benign paroxysmal positional vertigo: Diagnostic criteria. J Vestib Res 2015;25:105–17

    Article  Google Scholar 

  9. Bremova T, Bayer O, Agrawal Y, Kremmyda O, Brandt T, Teufel J, Strupp M. Ocular VEMPs indicate repositioning of otoconia to the utricle after successful liberatory maneuvers in benign paroxysmal positioning vertigo. Acta Otolaryngol 2013;133:1297–1303

    Article  Google Scholar 

  10. Brandt T, Huppert D, Hecht J, Karch C, Strupp M. Benign paroxysmal positioning vertigo: a long-term follow-up (6-17 years) of 125 patients. Acta Otolaryngol 2006;126 (2):160-3

    Google Scholar 

  11. AlGarni MA, Mirza AA, Althobaiti AA, Al-Nemari HH, Bakhsh LS. Association of benign paroxysmal positional vertigo with vitamin D deficiency: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2018;275:2705–11

    Article  Google Scholar 

  12. Sheikhzadeh M, Lotfi Y, Mousavi A, Heidari B, Bakhshi E. The effect of serum vitamin D normalization in preventing recurrences of benign paroxysmal positional vertigo: A case-control study. Caspian J Intern Med 2016;7:173–7

    PubMed  PubMed Central  Google Scholar 

  13. Jeong SH, Kim JS, Kim HJ, Choi KD, Park JY, Lee SH, Choi SY, Oh SY, Choi JY, Park JH, Kim SH, Jung I. OP28-5 - Supplementation of Vitamin D and Calcium May Prevent Recurrences of BPPV. J Vest Res 2018;28:98–9

    Google Scholar 

  14. Strupp M, Magnusson M. Acute Unilateral Vestibulopathy. Neurol Clin 2015;33:669–85

    Article  Google Scholar 

  15. Beck R, Gunther L, Xiong G, Potschka H, Boning G, Bartenstein P, et al. The mixed blessing of treating symptoms in acute vestibular failure—evidence from a 4-aminopyridine experiment. Exp Neurol 2014;261:638–45

    Article  CAS  Google Scholar 

  16. Strupp M, Zingler VC, Arbusow V, Niklas D, Maag KP, Dieterich M, et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004;351:354–61

    Article  CAS  Google Scholar 

  17. Karlberg ML, Magnusson M. Treatment of acute vestibular neuronitis with glucocorticoids. Otol Neurotol 2011;32:1140–3

    Article  Google Scholar 

  18. Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 2011;(5):CD008607

  19. Chabbert C. Principles of vestibular pharmacotherapy. Handb Clin Neurol 2016;137:207–18

    Article  CAS  Google Scholar 

  20. Hamann. Special ginkgo extract in cases of vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO 2007;55(4):258–63

    Article  Google Scholar 

  21. Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandala M, Newman-Toker DE, Strupp M, Suzuki M, Trabalzini F, Bisdorff A: Diagnostic criteria for Meniere’s disease. J Vestib Res 2015;25:1–7

    PubMed  Google Scholar 

  22. Stokroos R, Kingma H. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Meniere’s disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol 2004;124:172–5

    Article  CAS  Google Scholar 

  23. Postema RJ, Kingma CM, Wit HP, Albers FW, Van Der Laan BF. Intratympanic gentamicin therapy for control of vertigo in unilateral Meniere’s disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol 2008;128:876–80

    Article  CAS  Google Scholar 

  24. Pullens B, van Benthem PP. Intratympanic gentamicin for Meniere’s disease or syndrome. Cochrane Database Syst Rev 2011;(3):CD008234

  25. Garduno-Anaya MA, Couthino De TH, Hinojosa-Gonzalez R, Pane-Pianese C, Rios-Castaneda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere’s disease: a two-year prospective,placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005;133(2):285–94

    Article  Google Scholar 

  26. Patel M, Agarwal K, Arshad Q, Hariri M, Rea P, Seemungal BM, Golding JF, Harcourt JP, Bronstein AM. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière’s disease: a randomised, double-blind, comparative effectiveness trial. Lancet 2016;388(10061):2753–62

    Article  CAS  Google Scholar 

  27. Nauta JJ. Meta-analysis of clinical studies with betahistine in Meniere’s disease and vestibular vertigo. Eur Arch Otorhinolaryngol 2014;271(5):887–97

    Article  Google Scholar 

  28. Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M; BEMED Study Group. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016;352:h6816. doi: https://doi.org/10.1136/bmj.h6816

    Article  Google Scholar 

  29. Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in Guinea pigs in vivo. PLoS One 2012; 7(6):e39086

    Article  CAS  Google Scholar 

  30. Strupp M, Kraus L, Schautzer F, Rujescu D. Menière’s disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study. J Neurol 2018;265:80–5

    Article  CAS  Google Scholar 

  31. Strupp M, Lopez-Escamez JA, Kim JS, Straumann D, Jen JC, Carey J, Bisdorff A, Brandt T.Vestibular paroxysmia: Diagnostic criteria. J Vestib Res. 2016;26(5-6):409–15

    Article  Google Scholar 

  32. Maldonado FM, Birdi JS, Irving GJ, Murding L, Kivekäse I, Strupp M. Pharmacological treatment for the prevention of vestibular migraine. Cochrane Database of Systematic Reviews. 2015; Jun 21;(6):CD010600

  33. Strupp M, Lopez-Escamez JA, Kum JS, Straumann D, Jen JC, Carey J, Bisdorff A, Brandt T. Vestibular paroxysmia: Diagnostic criteria. J Vest Res 2016; 26(5-6):409–15

    Article  Google Scholar 

  34. Bayer O, Brémová T, Strupp M, Hüfner K. A randomized double-blind, placebo-controlled, cross-over trial (Vestparoxy) of the treatment of vestibular paroxysmia with oxcarbazepine. J Neurol. 2018;265(2):291–8

    Article  CAS  Google Scholar 

  35. Feil K, Strobl R, Schindler A, Krafczyk S, Goldschagg N, Frenzel C, Glaser M, Schöberl F, Zwergal A, Strupp M. What Is Behind Cerebellar Vertigo and Dizziness? Cerebellum 2018 Dec 14. doi: https://doi.org/10.1007/s12311-018-0992-8

  36. Strupp M, Teufel J, Zwergal A, Schniepp R, Khodakhah K, Feil K. Aminopyridines for the treatment of neurologic disorders. Neurol Clin Pract 2017;7(1):65–76

    Article  Google Scholar 

  37. Strupp M, Schuler O, Krafczyk S, Jahn K, Schautzer F, Buttner U, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 2003;61(2):165–70

    Article  CAS  Google Scholar 

  38. Claassen J, Spiegel R, Kalla R, Faldon M, Kennard C, Danchaivijitr C, et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 2013;84(12):1392–9

    Article  Google Scholar 

  39. Feil K, Claaßen J, Bardins S, Teufel J, Krafczyk S, Schneider E, Schniepp R, Jahn K, Kalla R, Strupp M. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial. Neurology. 2013;81(13):1152–8

    Article  CAS  Google Scholar 

  40. Schniepp R, Wuehr M, Neuhaeusser M, Benecke AK, Adrion C, Brandt T, et al. 4-Aminopyridine and cerebellar gait: a retrospective case series. J Neurol 2012;259(11):2491–3

    Article  Google Scholar 

  41. Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP, et al. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol 2013;260(10):2556–61

    Article  Google Scholar 

  42. Bremova T, Malinová V, Amraoui Y, Mengel E, Reinke J, Kolníková M, Strupp M. Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology. 2015;85(16):1368–75

    Article  CAS  Google Scholar 

  43. Strupp M, Dieterich M, Zwergal A, Brandt T. Diagnosis and treatment options in vertigo syndromes. Nervenarzt 2015;86(10):1277–90

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andreas Zwergal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zwergal, A., Strupp, M. Medikamentöse Therapie bei Schwindel: Was gibt es Neues?. DNP 20, 41–46 (2019). https://doi.org/10.1007/s15202-019-2172-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-019-2172-1

Navigation